Business Wire

ASU Prep Digital Teams Up With Google Public Sector to Develop Streaming Educational Curriculum With Universal Access

13.7.2022 14:00:00 EEST | Business Wire | Press release

Share

ASU Prep Digital, an accredited online K-12 school offered through Arizona State University, has partnered with Google Public Sector, to make remote immersive learning technology more accessible to students across the United States and around the world. ASU Prep Learning Cloud is a streaming solution that empowers schools to deliver innovative and interactive 3D learning experiences to students using low-bandwidth devices. The technology was developed on and is powered by Google Cloud.

This new platform invites students to solve challenges by immersing themselves in interactive settings made possible by technology. For example, students can watch geologic formations emerge through simulations rather than reading about it in a textbook. Students can also explore human organs in 3D or examine a plastic mannequin. This brings topics like erosion, hydrolysis, and human anatomy to life.

To successfully complete a lesson, students must think critically about the concept, explore it, and learn through discovery. Real-time, instructive feedback also helps contribute to a more individualized learning experience.

“We’re turning students into explorers by embedding learning into the digital formats that students love,” said David Sudarma, ASU Prep’s chief technology officer. “We spark curiosity by asking students to navigate 3D worlds, hypothesize, and discover knowledge by manipulating game-like simulations to solve real-world problems.”

Advancing Accessibility

The ASU Prep Learning Cloud represents an important step toward accessibility for students in rural areas, with limited broadband access, and districts where limited technology funding makes it difficult to deliver cutting-edge learning opportunities. This immersive cloud-based education technology can be experienced from mobile devices or Chromebooks, increasing accessibility for all learners, anytime, anywhere. Removing those barriers is especially important for a program like ASU Digital Prep, which can be instrumental in bridging gaps for districts where resources are slim.

“ASU Prep Digital has allowed us to partner and advance educational opportunities for thousands of K-12 students who might not have otherwise had access to the courses, credits, mentors, and teachers we offer,” said Arizona State University President Michael Crow, who is widely known as a pioneer of online education.

Crow’s vision has created a tech-enhanced learning environment across ASU, inclusive of pre-collegiate students via ASU Prep Digital. A key element of that vision is expanded opportunities in online education, which offers a path to higher education for students who are otherwise hindered from pursuing their education goals. In addition to its rapidly expanding K-12 enrollment, ASU Prep Digital’s School Partnerships continue to grow. The program supports entire school districts in states like Utah, Louisiana and Ohio, as well as schools in 22 states and 12 countries.

Powerhouse Partnerships

In addition to the full- and part-time students who enroll directly with ASU Prep Digital, the school also teams with private schools, public schools, and districts worldwide to offer a K-12 curriculum and one-on-one instruction in a virtual environment. The program’s latest suite of courses, which will be available this fall to partner schools via the ASU Prep Learning Cloud, powered by Google Cloud, can be used in compliance with Family Educational Rights and Privacy Act (FERPA).

As pioneers in their respective industries, ASU Prep Digital and Google Public Sector worked to develop the platform, which is based on game engine technology. The ASU Prep Learning Cloud features responsive design optimized for the most commonly used devices (e.g., Chromebooks, mobile phones) using Web Content Accessibility Guidelines (WCAG).

“Our partnership with ASU Prep Digital has the ability to unlock new and innovative academic opportunities for learners across the country,” said Steven Butschi, director of Education, Google Public Sector. “We’re unleashing the power of Google Cloud to help make individualized, digital, and interactive learning the new standard in education.”

Courses integrate seamlessly into existing learning management systems, while supporting robust interactive features that personalize learning. The platform currently supports ASU Prep Digital partner schools, but in the future, could be rolled out to other educational institutions.

“As immersive technologies become more widely adapted in education, 3D learning environments such as augmented reality and virtual reality offer great potential for engagement and retention,” Sudarma said. “Our collaboration with Google Public Sector is a terrific first step in expanding access to immersive solutions across many devices, and we’re working together to explore ways immersive technologies can be made even more universally available to eager learners.”

To preview a snapshot of ASU Prep Learning Cloud courses, visit: https://vimeo.com/623494408 or take a deeper look at the immersive platform here: https://vimeo.com/689344144/795e785a7c

About ASU Prep Digital

ASU Prep Digital is an accredited online K-12 school that offers a single online course or enrollment in a full-time, diploma-granting program. Because it is part of Arizona State University, ASU Prep Digital offers an accelerated path toward college admission and the chance to earn concurrent high school and university credit. For more information, visit asuprepdigital.org.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Contact: Angela Menninger, angela@dualitypr.com or (602) 373-8212 (m)

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye